Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05318183

Assessing Gut Microbiota Mediated Health Outcomes of Whole Wheat and Its Major Bioactive Components

This study will investigate the gut microbiota-mediated effects of whole wheat consumption on human health in adults with pre-diabetes. Participants will complete two phases of intervention in random order in which they will consume either whole wheat bread (4 servings) or white bread a day for two weeks prior to collecting specimens (stool, urine, and plasma/serum).

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

About this study

Accumulating clinical evidence suggests positive effects of whole grain on cardiometabolic risk. However, outcomes of controlled trials indicate that substantial interpersonal variation occurs in these studies with regard to glucose homeostasis, with some persons being unaffected and others experiencing glucose-lowering effects due to whole wheat bread consumption. Whole grain (whole wheat) contains bioactive phytochemicals in addition to its well-recognized fiber content, and these constituents have not received adequate study to inform dietary recommendations. The objective of this study is to investigate the glucose-lowering effects of whole wheat bread in persons with prediabetes using multi-omics platforms that can provide an understanding of the complex interactions among the gut microbiome, gut metabolome, host metabolome, and gut barrier function. The hypothesis is that gut microbial metabolism of whole wheat and its major bioactive components is a determining factor of human health benefits. This will be tested by conducting a randomized, controlled crossover trial in persons with pre-diabetes who follow a controlled diet containing whole wheat bread or white bread for 2-weeks. Outcomes are expected to significantly advance an understanding of personalized, gut microbiome-mediated approaches in individuals with pre-diabetes to help guide dietary recommendations of whole wheat intake. In addition, novel evidence that maps out the differential functions of diverse genus/species of microbiota to biotransform whole wheat nutrients into more bioactive metabolites are expected.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Fasting blood glucose between 100-125 mg/dL
  • BMI of 30-35 kg/m2

Exclusion criteria

  • History of liver disease, cardiovascular disease, overt diabetes, or cancer
  • Prescribed medications for hyperglycemia or dyslipidemia
  • Use of dietary supplements, prebiotics, or probiotics
  • Usage of antibiotics or anti-fungals within 3 months prior to enrollment
  • Smoker
  • Alcohol consumption greater than 2 drinks per day
  • Aerobic exercise greater than 5 hours per week
  • Pregnancy or fertility treatments
  • History of chronically active inflammatory or neoplastic disease in 3 years prior to enrollment
  • History of chronic gastrointestinal disorder including diarrhea, inflammatory bowel disease, celiac disease; coagulation disorders, chronic immunosuppressive medication usage
  • History of myocardial infarction or cerebrovascular accident within 6 months prior to participation

Treatment and study plan

Whole wheat bread

Other

Standardized whole wheat bread (128 g daily)

White Bread (control)

Other

Standardized white bread (128 g daily)

Primary outcomes

  1. Plasma Glucose

    Time frame: Day 14 (0, 30, 60, 90, 120, 150, 180 minutes post oral glucose tolerance test)

    Data are biomarker area under the time-concentration curve (0-3 hours) on day 14

Secondary outcomes

  1. Plasma Insulin

    Time frame: Day 14

    Data are biomarker fasting concentrations

  2. Plasma Glucose

    Time frame: Day 14

    Data are biomarker fasting concentrations.

  3. Serum C-reactive Protein

    Time frame: Day 14

    Data are the biomarker serum concentration of C-reactive protein.

  4. Serum Tumor Necrosis Factor Alpha

    Time frame: Day 14

    Data are biomarker serum tumor necrosis factor alpha concentrations.

  5. Serum Interleukin-6

    Time frame: Day 14

    Data are biomarker serum interleukin-6 concentrations.

  6. Fecal Calprotectin

    Time frame: Day 14

    Data are biomarker fecal concentrations.

  7. Fecal Myeloperoxidase

    Time frame: Day 14

    Data are biomarker fecal concentrations.

  8. Urine Lactulose/Mannitol

    Time frame: Day 14

    Data are the 24-hour urinary excretion ratio of lactulose relative to mannitol collected 0-5 h following the digestion of non-digestible sugar probes.

  9. Urine Sucralose/Erythritol

    Time frame: Day 14

    Data are the sucralose/erythritol ratio measured in urine collected 6-24 h following the digestion of non-digestible sugar probes.

  10. Serum Endotoxin

    Time frame: Day 14

    Data are biomarker fasting concentrations.

  11. Serum Myeloperoxidase

    Time frame: Day 14

    Data are biomarker serum concentrations.

  12. Level of Toll-like Receptor 4 Gene Expression

    Time frame: Day 14

    Data are expression of toll-like receptor 4 gene from peripheral blood mononuclear cells.

  13. Myeloid Differentiation Factor 88 Gene Expression

    Time frame: Day 14

    Expression of myeloid differentiation factor 88 gene from peripheral blood mononuclear cells.

  14. Tumor Necrosis Factor Alpha Gene Expression

    Time frame: Day 14

    Expression of tumor necrosis factor alpha gene from peripheral blood mononuclear cells.

  15. p65 Subunit of Nuclear Factor Kappa B Gene Expression

    Time frame: Day 14

    Expression of p65 subunit of nuclear factor kappa B gene from peripheral blood mononuclear cells.

  16. Interleukin-6 Gene Expression

    Time frame: Day 14

    Expression of interleukin-6 gene from peripheral blood mononuclear cells.

  17. Interleukin-8 Gene Expression

    Time frame: Day 14

    Expression of interleukin-8 gene from peripheral blood mononuclear cells.

  18. Myeloperoxidase Gene Expression

    Time frame: Day 14

    Expression of myeloperoxidase gene from peripheral blood mononuclear cells.

  19. Monocyte Chemoattractant Protein-1 Gene Expression

    Time frame: Day 14

    Expression of monocyte chemoattractant protein-1 gene from peripheral blood mononuclear cells.

  20. Fecal Butyrate

    Time frame: Day 14

    Data are biomarker fecal concentrations.

  21. Fecal Acetate

    Time frame: Day 14

    Data are biomarker fecal concentrations.

  22. Fecal Propionate

    Time frame: Day 14

    Data are biomarker fecal concentrations.

  23. Fecal Isobutyric Acid

    Time frame: Day 14

    Data are biomarker fecal concentrations.

  24. Fecal Isovaleric Acid

    Time frame: Day 14

    Data are biomarker fecal concentrations of isovaleric acid.

  25. Serum Alkylersorcinols

    Time frame: Day 14

    Data are biomarker serum concentrations of alkylresorcinol and alkylresorcinol derivatives.

  26. Serum Benoxazinods

    Time frame: Day 14

    Data are biomarker serum concentrations of benoxazinoids and benoxazinoids derivatives.

  27. Serum Phenolic Compounds

    Time frame: Day 14

    Data are biomarker serum concentrations of phenolic compounds and phenolic derivatives.

  28. Fecal Alkylresorcinols

    Time frame: Day 14

    Data are biomarker fecal concentrations of alkylresorcinols and alkylresorcinol derivatives.

  29. Fecal Benoxazinoids

    Time frame: Day 14

    Data are biomarker fecal concentrations of benoxazinoids and benoxazinoids derivatives.

  30. Fecal Phenolic Compounds

    Time frame: Day 14

    Data are fecal concentrations of phenolic compounds and phenolic derivatives.

Other outcomes

  1. Plasma Triglyceride

    Time frame: Day 0, Day 14

    Data are biomarker fasting plasma concentrations.

  2. Plasma Cholesterol Levels

    Time frame: Day 14

    Data are biomarker fasting plasma concentrations.

  3. Plasma HDL-cholesterol

    Time frame: Day 14

    Data are biomarker fasting plasma concentrations.

  4. Serum Alanine Transaminase

    Time frame: Day 14

    Data are biomarker serum concentrations of alanine transaminase.

  5. Serum Interleukin-8

    Time frame: Day 14

    Data are biomarker serum interleukin-8 concentrations.

  6. Gut Microbiota Alpha-diversity Indices

    Time frame: Day 14

    Alpha-diversity will be determined based on the Shannon-Wiener diversity index. Fecal microbiota assessments and the subsequent determinations of alpha-diversity.

  7. Gut Microbiota Beta-diversity Indices

    Time frame: Day 14

    Beta-diversity will be determined based on the Bray-Curtis diversity index. Fecal microbiota assessments and the subsequent determinations of beta-diversity.

  8. Gut Microbiota Relative Abundance

    Time frame: Day 14

    Gut microbiota relative abundance (percent order, genus, and species level) will be measured in fecal samples.

Sponsors and collaborators

Lead sponsor

Ohio State University

Other

Collaborators

  • United States Department of Agriculture (USDA)

Registry information

Important dates

Study start
2022
Primary completion
2024
Study completion
2026
First posted
Apr 8, 2022
Registry last updated
Nov 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.